Back
HFA Premium Access

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

Session: Moderated Poster session 3 - Novel treatment
Topic: Cardiotoxicity of Drugs and Other Therapies
Event: Heart Failure 2018

Congress Presentation

Add to my library

Like

6 more presentations in this session

What proportion of patients with HFrEF might be candidates for Sacubitril-Valsartan?

Speaker: Doctor T. O connor (Dublin 9, IE)

Access
Abstract
Slides
Like
Thumbnail

Heart failure patients with reduced left ventricular ejection fraction, who reached 100% target dose of beta-blockers in randomized and observational studies

Speaker: Mrs M. Oyanguren Artola (Bilbao, ES)

Access
Abstract
Slides
Like
Thumbnail

Metabolic response to exercise training in heart failure with preserved ejection fraction

Speaker: Doctor M. Bahls (Greifswald, DE)

Access
Abstract
Like
Thumbnail

Adherence to ESC guidelines after hospital admission for heart failure in 22500 Dutch patients: 2001-2015

Speaker: Mrs W. Kruik-Kolloffel (Almelo, NL)

Access
Abstract
Slides
Like
Thumbnail

Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure

Speaker: Doctor S. Zheng (London, GB)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Moderated Poster session 3 - Novel treatment

Speakers: Doctor T. O connor, Mrs M. Oyanguren Artola, Doctor M. Bahls, Mrs W. Kruik-Kolloffel, Doctor S. Zheng
Access
Like
Thumbnail

About the event

Image

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources